Horizon Therapeutics, a biotech company focused on rare, autoimmune and severe inflammatory diseases, sued Teva Pharmaceuticals on April 5 in Delaware District Court over patent infringement claims. The court case, asserting 14 patents related to the plaintiff's treatment for urea cycle disorders, Ravicti, was brought by Young Conaway Stargatt & Taylor and Gibson, Dunn & Crutcher. The suit seeks to enjoin Teva from manufacturing generic versions of Ravicti. Lawyers have not yet appeared for the defendant. The case is 1:24-cv-00432, Horizon Therapeutics U.S. Holding LLC v. Teva Pharmaceuticals, Inc.
Biotech & Pharmaceuticals
April 05, 2024, 5:40 PM